about
Pharmacokinetics, brain distribution and plasma protein binding of carbamazepine and nine derivatives: new set of data for predictive in silico ADME models.Enantioselective HPLC-UV method for determination of eslicarbazepine acetate (BIA 2-093) and its metabolites in human plasma.Development and validation of a fast isocratic liquid chromatography method for the simultaneous determination of norfloxacin, lomefloxacin and ciprofloxacin in human plasma.A chiral liquid chromatography method for the simultaneous determination of oxcarbazepine, eslicarbazepine, R-licarbazepine and other new chemical derivatives BIA 2-024, BIA 2-059 and BIA 2-265, in mouse plasma and brain.Chiral chromatographic resolution of antiepileptic drugs and their metabolites: a challenge from the optimization to the application.Development of a liquid chromatography assay for the determination of opicapone and BIA 9-1079 in rat matrices.Intranasal drug delivery: how, why and what for?Analytical methods for determination of new fluoroquinolones in biological matrices and pharmaceutical formulations by liquid chromatography: a review.Liquid chromatographic methods for the quantification of catecholamines and their metabolites in several biological samples--a review.A critical review of microextraction by packed sorbent as a sample preparation approach in drug bioanalysis.Third and fourth generation fluoroquinolone antibacterials: a systematic review of safety and toxicity profiles.Intranasal delivery of systemic-acting drugs: small-molecules and biomacromolecules.Blood-brain barrier models and their relevance for a successful development of CNS drug delivery systems: a review.Screening of pharmacokinetic properties of fifty dihydropyrimidin(thi)one derivatives using a combo of in vitro and in silico assays.Drug-metabolizing Enzymes and Efflux Transporters in Nasal Epithelium: Influence on the Bioavailability of Intranasally Administered Drugs.P-glycoprotein Mediated Efflux Modulators of Plant Origin: A Short Review.Intranasal Delivery of Topically-Acting Levofloxacin to Rats: a Proof-of-Concept Pharmacokinetic Study.Intranasal delivery of ciprofloxacin to rats: A topical approach using a thermoreversible in situ gel.Enantioselective assay for therapeutic drug monitoring of eslicarbazepine acetate: no interference with carbamazepine and its metabolites.Binding of licarbazepine enantiomers to mouse and human plasma proteins.Development and validation of an HPLC-UV method for the simultaneous quantification of carbamazepine, oxcarbazepine, eslicarbazepine acetate and their main metabolites in human plasma.An HPLC-DAD method for the simultaneous quantification of opicapone (BIA 9-1067) and its active metabolite in human plasma.Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-O-Methyltransferase Inhibitors.Flavonoid compounds as reversing agents of the P-glycoprotein-mediated multidrug resistance: An in vitro evaluation with focus on antiepileptic drugs.A new PAMPA model using an in-house brain lipid extract for screening the blood-brain barrier permeability of drug candidates.Direct nose-to-brain delivery of lamotrigine following intranasal administration to mice.Determination of catecholamines and endogenous related compounds in rat brain tissue exploring their native fluorescence and liquid chromatography.Intranasal administration of carbamazepine to mice: a direct delivery pathway for brain targeting.In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein.A single- and multiple-dose study to investigate the pharmacokinetics and pharmacodynamics of opicapone, a novel COMT inhibitor, in rat.Pharmacokinetics of opicapone, a third-generation COMT inhibitor, after single and multiple oral administration: A comparative study in the rat.First liquid chromatography method for the simultaneous determination of levofloxacin, pazufloxacin, gatifloxacin, moxifloxacin and trovafloxacin in human plasma.Development and full validation of an innovative HPLC-diode array detection technique to simultaneously quantify lacosamide, levetiracetam and zonisamide in human plasma.Liquid chromatographic assay based on microextraction by packed sorbent for therapeutic drug monitoring of carbamazepine, lamotrigine, oxcarbazepine, phenobarbital, phenytoin and the active metabolites carbamazepine-10,11-epoxide and licarbazepine.First HPLC–UV method for rapid and simultaneous quantification of phenobarbital, primidone, phenytoin, carbamazepine, carbamazepine-10,11-epoxide, 10,11-trans-dihydroxy-10,11-dihydrocarbamazepine, lamotrigine, oxcarbazepine and licarbazepine in humErratum to: Analytical methods for determination of new fluoroquinolones in biological matrices and pharmaceutical formulations by liquid chromatography: a reviewEvaluation of the permeability and P-glycoprotein efflux of carbamazepine and several derivatives across mouse small intestine by the Ussing chamber techniqueOptimization of a Parallel Artificial Membrane Permeability Assay for the Fast and Simultaneous Prediction of Human Intestinal Absorption and Plasma Protein Binding of Drug Candidates: Application to Dibenz[b,f]azepine-5-Carboxamide DerivativesA chiral HPLC-UV method for the quantification of dibenz[b,f]azepine-5-carboxamide derivatives in mouse plasma and brain tissue: Eslicarbazepine acetate, carbamazepine and main metabolitesHerb-drug pharmacokinetic interaction between carica papaya extract and amiodarone in rats
P50
Q30667842-8B90FF68-70BE-49A6-9A54-A397A82433F7Q33289016-39ED7D0E-CDA5-44B3-AD2F-FAA5E15E44A6Q33635606-939D3E7D-40F2-41F1-91AC-4BFCB8A54C81Q33968508-AAC59088-D29C-4192-8070-A51CABD94540Q34941977-0F87F215-751C-4312-A9EE-BA02E847DD18Q35683786-1189C79A-9796-4502-91BD-80B65BD8DCB6Q37672691-2A3EF981-77CB-42B4-B184-05E77DA46BD3Q37982661-2BC84A1E-1E5B-4B68-82B7-E02E5B98393AQ38087673-DFA51EAA-C80D-4F37-AFDC-8E73ABC0C8CEQ38112479-FDDCDF31-5DD6-46CD-8179-C800061579BEQ38177309-DB64087E-E303-41EE-B9D0-83FDE0E3864DQ38200422-7FF370D1-D45E-44EB-BED0-BE5451B3DFCBQ38200847-8BEE43AE-99DD-487A-B202-10BE075D1A13Q38607765-43E5B9F9-D880-4808-99EF-5CD7E1E73B9BQ38798867-88A15D5A-2D2C-4351-BF07-CA37E85F4B1FQ38869655-88ABA7E4-043A-44AF-86C6-75A27E7FE01EQ40117762-6E1677C0-E042-4A5E-9FA9-81F9D43BDAF9Q40465025-51F2477D-E5B9-44DD-B30C-934CA2EEFEA5Q42997433-E599A1B0-31B9-4254-918F-C066FB7C5942Q43005689-12E25176-69EE-4D93-BE3C-D0220512B2F6Q43094332-56336FDC-3A54-4B21-B593-E1FCDE9161B2Q43734498-0DEDCF9D-C8B8-415A-B686-221499CCEE61Q47793935-C14E66D5-37B0-4B2A-866E-560C2AE39A34Q47802914-61C5E715-DBDA-4E95-9A28-08AA434E3368Q47885529-4872FD5B-794D-4A7C-812A-CB53E6BADFFEQ48174435-1BCCBD88-1893-41FD-A4F2-373E984A6736Q48273528-523D9B3B-0D4D-4752-B875-EAC814CE463EQ48783221-01C30BE7-46A2-4A2C-94F7-EA1A9E65FBF8Q50082470-A2B1D0D6-6F31-427B-86E8-EF481E999A98Q50522590-B0A2C217-F0AD-4E5E-AC8C-4D64407C60BEQ50786033-9614E697-2DC8-4420-9417-D529B32D506CQ50944720-000E5C4B-837E-4E51-9AA0-72D13E976788Q52645100-54DC798F-AFBC-4845-9224-7E0AE24E83CDQ53155134-56B0B14F-BF9E-42C4-82F9-6FBC944A80A8Q60405059-5F0142BD-DCEB-4A58-B249-B8A82FC0B0D0Q60405073-102A1F09-1A1C-4433-944A-285B09B1D18CQ60405076-39670DF0-B48E-4119-9974-49A4BC8C5706Q60405079-9AB2B96B-D31E-4E70-B7FA-95722FA8294CQ60405085-C7B95072-800E-4DEE-9F65-913B456018BEQ85316524-A99CD946-6122-4DAB-B226-AC8C4132144E
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ana Fortuna
@ast
Ana Fortuna
@en
Ana Fortuna
@es
Ana Fortuna
@nl
type
label
Ana Fortuna
@ast
Ana Fortuna
@en
Ana Fortuna
@es
Ana Fortuna
@nl
prefLabel
Ana Fortuna
@ast
Ana Fortuna
@en
Ana Fortuna
@es
Ana Fortuna
@nl
P106
P1153
36941957200
P21
P31
P496
0000-0001-6981-6639